Navigation Links
Up to 20 million euros for Munich Catalysis research cooperation
Date:11/29/2010

Sd-Chemie AG and Technische Universitaet Muenchen (TUM) have formed a strategic alliance for catalysis research, "Munich Catalysis." In addition to basic research in the field of catalysis, a major aspect of this cooperation will be the development of innovative catalysts as a key technology to help meet the rising global demand for energy and base chemicals on a long-term basis. Sd-Chemie is to sponsor this research work with up to two million euros a year. The cooperation is based on a master agreement concluded for an initial term of ten years, which, if successful, is to be extended beyond this period.

Activities are due to start before the end of the year under the name "Munich Catalysis. Alliance of Sd-Chemie and TUM." Based on an industry-on-campus concept, TUM scientists will be working together with researchers from Sd-Chemie on central issues involving both basic and applied research in the field of chemical catalysis.

In addition to developing innovative catalysts and preparation methods, research will focus on identifying new ways of manufacturing basic chemicals, one of the key topics being the inert gas carbon dioxide. Among other things, the possibilities for efficiently separating this omnipresent so-called greenhouse gas from power plant processes and reusing it in chemical production cycles are to be explored, for instance as a synthesis module in the manufacture of energy sources or other base chemicals. Attention will also center on new ways of creating high-grade intermediate products for plastics, so-called olefins, without using oil.

Catalysis is seen as a vital technology for industrial materials conversion processes in the 21st century. Catalysts make it possible for most chemical products to be manufactured using low-energy and resource-sparing processes. They also play an essential role in promoting the targeted replacement of oil as a primary resource for the chemical industry by assisting in the manufacture of chemical products based on alternative resources, such as natural gas, coal or renewable (biogenic) raw materials.

This strategic cooperation will play an important role in the TUMs overall strategy of bundling university research activities in the field of chemical catalysis. The research alliance is to be integrated into a new central institute for catalysis research set up by the TUM (Catalysis Research Center, CRC). As from 2012, it will be housed in the new CRC building currently under construction on the TUM campus in Garching. The CRC bundles the TUMs broad scientific spectrum in the field of catalysis research with focus on industry-related research.

"The overriding goal envisaged by Munich Catalysis is to develop key catalytic technologies on a sustainable basis which in view of the limited fossil resources and a continuing rise in the global consumption of energy and base chemicals make the greatest demands on research alliances between university and industry," says the TUMs President, Professor Wolfgang A. Herrmann. "As an entrepreneurial university, our research activities pursue the path of innovation to the stage of technical realization. In the field of catalysis, we have selected Sd-Chemie since this partner has a globally successful catalyst business."

Upon signing the agreement, Dr. Gnter von Au, Managing Board Chairman of Sd-Chemie AG, said: "Chemical catalysis is a key technology and will be making a major contribution to the development of economically and ecologically sustainable ways of manufacturing fuel and chemicals in times when resources are in increasingly short supply. This pioneering venture is a means of bundling our numerous scientific cooperation projects with the TUM in the field of catalysis research based on a future-oriented and highly efficient industry-on-campus concept. In this way, we will continue to strengthen the TUMs academic base in this high-potential sector, while also achieving a sustained improvement in Sd-Chemies innovative strength."


'/>"/>

Contact: Dr. Andreas Battenberg
battenberg@zv.tum.de
49-892-891-0510
Technische Universitaet Muenchen
Source:Eurekalert  

Related biology news :

1. Researcher explores the evolution of largest mammals over the past 100 million years
2. $1.6 million to take forward breakthrough research in heart disease
3. NIH awards $10 million to advance microneedle patch for flu vaccination
4. Aeras awarded €11.7 million ($16 million) grant from Dutch government
5. $2.7 million research award to aid nursery, floriculture industry
6. New statistical model moves human evolution back 3 million years
7. Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC
8. USAID awards $5 million to CONRAD
9. $12 million grant to probe root causes of heart failure
10. MegaMatcher Accelerator 3.0 for Rapid Biometric Identification Matches Up to 200 Million Irises or 100 Million Fingerprints Per Second
11. NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Up to 20 million euros for Munich Catalysis research cooperation
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: